Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan Conditioning for HSCT in Severe Aplastic Anemia
NCT06069180Phase 4Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of busulfan in aplastic anemia (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Failure Free Survival at 1 year. Started Nov 2023; status: recruiting.
02
Drugs
busulfan
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06069180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06069180.